HOME >> MEDICINE >> NEWS
Phase II study shows combination improves survival of metastatic melanoma patients

ew blood vessels from forming and allows the chemotherapy to work.

Fifty-three patients were treated with carboplatin, weekly treatments of paclitaxel (Taxol) and biweekly bevacizumab. Researchers found that the treatment was well tolerated and prevented the tumor from spreading from eight to nearly 24 weeks.

The number of new melanoma cases has continued to rise at a rate of about 5 percent to 10 percent each year since the 1970s, Dr. Markovic says. Why" One cause, he says, is depletion of the ozone layer, but also, more cases are coming to light due to greater public awareness.

"The increase in incidence is a big worry, particularly when we still do not have an effective treatment. That's why this step, however small, is important," Dr. Markovic says.


'"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Jun-2007


Page: 1 2 3

Related medicine news :

1. GSK announces launch of largest ever Phase III trial in lung cancer treatment
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. Drug combination proves effective against myeloma in Phase I trial
4. Researchers present Phase 2 clinical results for Acologix AC-100
5. Positive results for ACRUXs lead product in US Phase 3 trial
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. GroPep starts Phase 1 infertility trial
8. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
9. Joint statement on Savvy Phase 3 trial in Ghana to test the effectiveness of Savvy Gel in preventing HIV
10. NIAID launches first Phase II trial of a global HIV/AIDS vaccine
11. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is a ... FASCP. The program was recently launched on March 1, and Dr. Wentz discussed ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
(Date:3/28/2017)... 2017  Medeon Biodesign, Inc., a ... to announce that the Company led and successfully ... Inc., a San Jose, CA ... orthopedic extremity applications.  The orthopedic ... due to procedure volume growth, lifestyle influences and ...
(Date:3/28/2017)... -- "US Cancer Generics Market Outlook 2022" report gives ... analysis related to the emergence and integration of ... US. The report analyzes various clinical and non-clinical ... drugs in recent years. The introduction of generics ... for various stake holders involved US cancer drug ...
Breaking Medicine Technology:
Cached News: